{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"All-cause mortality at 6 months will be recorded. Cause of death will be classified as related to cancer, myocardial infarction, PE, other cardiovascular or other disease state. Death will be attributed to PE if there is evidence to support an association with PE.","groups":[{"description":"apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months\n\nApixaban: apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months","id":"OG000","title":"Apixaban"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"6 months","title":"Frequency of All-cause Mortality","type":"SECONDARY","unitOfMeasure":"Participants"}